Development of lentiviral vectors specifically targeting CD4+ cells
Because of their central role in immunity, CD4+ T cells are a key target for genetic modification in many therapeutic applications, and lentiviral vectors with a VSV-G envelope are often used for this engineering. However, due to their broad tropism, these vectors are inadequate for cell-targeted in vivo gene delivery. Here, we explored using HIV-1 Env, which has a natural tropism towards these cells, as an alternative. We describe a three-plasmid vector production system to incorporate a panel of CCR5- or CXCR4-tropic Envs. These Env proteins are expressed from pCAG, a plasmid with reduced HIV-1 elements. We identify HIV-1 Env-incorporating vectors that can be produced with sufficient titres to specifically transduce primary CD4+ T cells in the context of in vitro mixed populations of peripheral blood mononuclear cells. We show efficient and specific transduction of HIV-1 Env vectors delivering an anti-CD19 chimeric antigen receptor (CAR). We demonstrate functional activity of the generated CD4+ CAR T cells, leading to the targeted killing of B cells in those mixed cell populations. Our methodology enables the production of HIV-1 Env-incorporating lentiviral vectors with defined CD4 targeted delivery, opening avenues for direct in vivo CAR T cell generation.
Authors
- Hataf Khan (ORCID: https://orcid.org/0000-0003-1128-0266)
- Luis Apolonia (ORCID: https://orcid.org/0000-0002-9451-6117)
- Conrad A. Vink (ORCID: https://orcid.org/0000-0001-6739-6669)
- Daniel Cox (ORCID: https://orcid.org/0000-0003-1426-005X)
- Nathalia Almeida (ORCID: https://orcid.org/0000-0003-3145-186X)
- Michael H. Malim (ORCID: https://orcid.org/0000-0002-7699-2064)
- Simon Chanas
- Michela Marongiu
Institutions
- King's College London (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Age UK (GB)
- GlaxoSmithKline Research & Development Limited (United Kingdom) (GB)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.64898/2026.11.12.765936
- Primary Topic
- Virus-based gene therapy research
- Type
- preprint
Funders
- GlaxoSmithKline
- Wellcome Trust
- Biotechnology and Biological Sciences Research Council